Results 211 to 220 of about 5,770,101 (353)
Advances in Neoantigen-Based Cancer Vaccines. [PDF]
Wu AC, Nakamura Y, Kiyotani K.
europepmc +1 more source
CRISPR/Cas9 has revolutionized the field of gene therapy, but delivery remains an outstanding issue. We propose a nonviral gold‐nanoparticle platform for co‐delivery of CRISPR/Cas9 ribonucleoprotein and long 2.1 kilobase dsDNA transgene constructs. This CRISPR‐AuNP is inexpensive to produce and mediate gene editing and DNA delivery in T cells and CD34+
Rachel A. Cunningham +8 more
wiley +1 more source
Neoantigen-Encoded Oncolytic Viruses as Personalized Cancer Vaccines. [PDF]
Alkayyal AA.
europepmc +1 more source
We developed an assay to distinguish cellular binding from internalization. Compatible with microscopy and high‐throughput screening, the method identifies ligand‐mediated uptake. Applying top candidates to a protein‐based DNA carrier enhanced transfection efficiency, providing a rational strategy to improve non‐viral gene delivery systems.
David Scherer +5 more
wiley +1 more source
Bright side of the dark genome: antigens for next-gen cancer vaccines. [PDF]
Wang XS, Fox BA.
europepmc +1 more source
Cancer vaccines: advances, hurdles, and future directions. [PDF]
Vlachostergios PJ.
europepmc +1 more source
The Role of miRNAs in Chicken Immune Regulation and Prospects for Disease‐Resistant Breeding
A schematic workflow illustrating the screening of disease‐resistant miRNAs and the generation of miRNA‐based disease‐resistant chickens via PGC‐mediated germline genome editing. ABSTRACT MicroRNAs (miRNAs) are emerging as pivotal regulators of the immune system, playing a decisive role in shaping disease resistance in chicken.
Qiangzhou Wang +10 more
wiley +1 more source
Therapeutic cancer vaccines in pancreatic cancer. [PDF]
Wang Y, Huang P, Li C, Tu S, Yang H.
europepmc +1 more source
Background Individuals with systemic autoimmune rheumatic diseases (SARDs) are at risk for worse acute and post‐acute COVID‐19 outcomes, though whether individuals with SARDs have longer persistence of viral antigens after COVID‐19 has not been studied.
Naomi J. Patel +18 more
wiley +1 more source

